Gentium to Report First Half 2013 Financial Results

company logo

VILLA GUARDIA (COMO), Italy, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it will report its financial results for the first half of 2013 on Tuesday, August 13, 2013 and will hold a conference call and live webcast at 7:00 a.m. ET / 13:00 p.m. CET, to discuss the results and provide a business update.

A press release detailing the results will be published prior to the event. To participate in the call, interested parties may dial 1 866 966 9439 (North America toll-free) or +44 (0) 1452 555 566 (international/toll) to register ten minutes before the call is scheduled to begin and use confirmation code 12154777. To access the live audio webcast or the subsequent archived recording, visit The event will be archived for replay for 30 days. The replay can be accessed on the Company's website, or at 1 866 247 4222 (North America toll-free) or +44 (0) 1452 55 00 00 (international/toll) using Conference ID 12154777.

About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the EMA both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to any financial forecast or the possibility of any future regulatory approval, may differ materially from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F filed with the Securities and Exchange Commission under the caption "Risk Factors."

CONTACT: Gentium S.p.A. Salvatore Calabrese, +39 031-5373-260 SVP Finance & Chief Financial Officer or The Trout Group Chelsea Wheeler , +1 646-378-2491

Source:Gentium S.p.A.